Home Healthcare Biotechnology Neoantigen Cancer Vaccine Market

Neoantigen Cancer Vaccine Market Size, Share & Trends Analysis Report By Product (Personalised Neoantigen Vaccine, Off-the-Shelf Neoantigen Vaccine), By Neoantigen Type (Synthetic Long Peptide, Nucleic Acid, Dendritic Cell, Tumour Cell), By Route of Administration (Intravenous, Intramuscular, Transdermal, Others), By Cell (Autologous, Allogenic), By Technology (RNA Sequencing, Whole Genome Sequencing, HLA Typing), By Delivery Mechanism (Liposomes, Virosomes, Gene Gun, Electroporation, Others), By Application (Lung, Melanoma, Gastrointestinal, Others), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Neoantigen Cancer Vaccine Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Personalised neo-antigen vaccine
    2. Off-the-shelf neoantigen vaccine
  2. Neoantigen Cancer Vaccine Market, By Neoantigen Type 2022-2034 (USD MILLION/ Units)
    1. Synthetic Long Peptide
    2. Nucleic acid
    3. Dendritic cell
    4. Tumour cell
  3. Neoantigen Cancer Vaccine Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Intravenous
    2. Intramuscular
    3. Transdermal
    4. Others
  4. Neoantigen Cancer Vaccine Market, By Cell 2022-2034 (USD MILLION/ Units)
    1. Autologous
    2. Allogenic
  5. Neoantigen Cancer Vaccine Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. RNA Sequencing
    2. Whole Genome Sequencing
    3. HLA Typing
  6. Neoantigen Cancer Vaccine Market, By Delivery Mechanism 2022-2034 (USD MILLION/ Units)
    1. Liposomes
    2. Virosomes
    3. Gene gun
    4. Electroporation
    5. Others
  7. Neoantigen Cancer Vaccine Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Lung
    2. Melanoma
    3. Gastrointestinal
    4. Brain cancer
    5. Others
  8. Regional Neoantigen Cancer Vaccine Market
    1. North America
      1. North America Neoantigen Cancer Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
      2. North America Neoantigen Cancer Vaccine Market By Neoantigen Type 2022-2034 (USD MILLION/ Units)
        1. Synthetic Long Peptide
        2. Nucleic acid
        3. Dendritic cell
        4. Tumour cell
      3. North America Neoantigen Cancer Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intramuscular
        3. Transdermal
        4. Others
      4. North America Neoantigen Cancer Vaccine Market By Cell 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      5. North America Neoantigen Cancer Vaccine Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Sequencing
        2. Whole Genome Sequencing
        3. HLA Typing
      6. North America Neoantigen Cancer Vaccine Market By Delivery Mechanism 2022-2034 (USD MILLION/ Units)
        1. Liposomes
        2. Virosomes
        3. Gene gun
        4. Electroporation
        5. Others
      7. North America Neoantigen Cancer Vaccine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Melanoma
        3. Gastrointestinal
        4. Brain cancer
        5. Others
      8. U.S.
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      9. Canada
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
    2. Europe
      1. Europe Neoantigen Cancer Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
      2. Europe Neoantigen Cancer Vaccine Market By Neoantigen Type 2022-2034 (USD MILLION/ Units)
        1. Synthetic Long Peptide
        2. Nucleic acid
        3. Dendritic cell
        4. Tumour cell
      3. Europe Neoantigen Cancer Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intramuscular
        3. Transdermal
        4. Others
      4. Europe Neoantigen Cancer Vaccine Market By Cell 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      5. Europe Neoantigen Cancer Vaccine Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Sequencing
        2. Whole Genome Sequencing
        3. HLA Typing
      6. Europe Neoantigen Cancer Vaccine Market By Delivery Mechanism 2022-2034 (USD MILLION/ Units)
        1. Liposomes
        2. Virosomes
        3. Gene gun
        4. Electroporation
        5. Others
      7. Europe Neoantigen Cancer Vaccine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Melanoma
        3. Gastrointestinal
        4. Brain cancer
        5. Others
      8. U.K.
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      9. Germany
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      10. France
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      11. Spain
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      12. Italy
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      13. Russia
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      14. Nordic
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      15. Benelux
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      16. Rest of Europe
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
    3. APAC
      1. APAC Neoantigen Cancer Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
      2. APAC Neoantigen Cancer Vaccine Market By Neoantigen Type 2022-2034 (USD MILLION/ Units)
        1. Synthetic Long Peptide
        2. Nucleic acid
        3. Dendritic cell
        4. Tumour cell
      3. APAC Neoantigen Cancer Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intramuscular
        3. Transdermal
        4. Others
      4. APAC Neoantigen Cancer Vaccine Market By Cell 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      5. APAC Neoantigen Cancer Vaccine Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Sequencing
        2. Whole Genome Sequencing
        3. HLA Typing
      6. APAC Neoantigen Cancer Vaccine Market By Delivery Mechanism 2022-2034 (USD MILLION/ Units)
        1. Liposomes
        2. Virosomes
        3. Gene gun
        4. Electroporation
        5. Others
      7. APAC Neoantigen Cancer Vaccine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Melanoma
        3. Gastrointestinal
        4. Brain cancer
        5. Others
      8. China
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      9. Korea
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      10. Japan
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      11. India
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      12. Australia
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      13. Taiwan
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      14. South East Asia
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      15. Rest of Asia-Pacific
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
    4. Middle East and Africa
      1. Middle East and Africa Neoantigen Cancer Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
      2. Middle East and Africa Neoantigen Cancer Vaccine Market By Neoantigen Type 2022-2034 (USD MILLION/ Units)
        1. Synthetic Long Peptide
        2. Nucleic acid
        3. Dendritic cell
        4. Tumour cell
      3. Middle East and Africa Neoantigen Cancer Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intramuscular
        3. Transdermal
        4. Others
      4. Middle East and Africa Neoantigen Cancer Vaccine Market By Cell 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      5. Middle East and Africa Neoantigen Cancer Vaccine Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Sequencing
        2. Whole Genome Sequencing
        3. HLA Typing
      6. Middle East and Africa Neoantigen Cancer Vaccine Market By Delivery Mechanism 2022-2034 (USD MILLION/ Units)
        1. Liposomes
        2. Virosomes
        3. Gene gun
        4. Electroporation
        5. Others
      7. Middle East and Africa Neoantigen Cancer Vaccine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Melanoma
        3. Gastrointestinal
        4. Brain cancer
        5. Others
      8. UAE
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      9. Turkey
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      10. Saudi Arabia
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      11. South Africa
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      12. Egypt
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      13. Nigeria
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      14. Rest of MEA
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
    5. LATAM
      1. LATAM Neoantigen Cancer Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
      2. LATAM Neoantigen Cancer Vaccine Market By Neoantigen Type 2022-2034 (USD MILLION/ Units)
        1. Synthetic Long Peptide
        2. Nucleic acid
        3. Dendritic cell
        4. Tumour cell
      3. LATAM Neoantigen Cancer Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intramuscular
        3. Transdermal
        4. Others
      4. LATAM Neoantigen Cancer Vaccine Market By Cell 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      5. LATAM Neoantigen Cancer Vaccine Market By Technology 2022-2034 (USD MILLION/ Units)
        1. RNA Sequencing
        2. Whole Genome Sequencing
        3. HLA Typing
      6. LATAM Neoantigen Cancer Vaccine Market By Delivery Mechanism 2022-2034 (USD MILLION/ Units)
        1. Liposomes
        2. Virosomes
        3. Gene gun
        4. Electroporation
        5. Others
      7. LATAM Neoantigen Cancer Vaccine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Melanoma
        3. Gastrointestinal
        4. Brain cancer
        5. Others
      8. Brazil
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      9. Mexico
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      10. Argentina
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      11. Chile
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      12. Colombia
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
      13. Rest of LATAM
        1. Personalised neo-antigen vaccine
        2. Off-the-shelf neoantigen vaccine
        3. Synthetic Long Peptide
        4. Nucleic acid
        5. Dendritic cell
        6. Tumour cell
        7. Intravenous
        8. Intramuscular
        9. Transdermal
        10. Others
        11. Autologous
        12. Allogenic
        13. RNA Sequencing
        14. Whole Genome Sequencing
        15. HLA Typing
        16. Liposomes
        17. Virosomes
        18. Gene gun
        19. Electroporation
        20. Others
        21. Lung
        22. Melanoma
        23. Gastrointestinal
        24. Brain cancer
        25. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.